
"I am glad that taking part in a trial might help others on their own cancer journey.”
This trial is looking at AZD1390 in combination with radiotherapy. It is for people who have 1 of the following:
Glioblastoma is one of the most common types of brain tumours in adults. Glioblastoma is also known as glioblastoma multiforme (GBM).
The usual treatment for glioblastoma is surgery to remove as much of the tumour as possible. After surgery, you usually have radiotherapy and chemotherapy. But sometimes the cancer comes back again.
There are a number of different treatments for cancer that has spread to the brain from another part of the body. This might include radiotherapy or chemotherapy.
Researchers are looking for ways to improve treatment for people who have:
In this trial, they are looking at a drug called AZD1390 alongside radiotherapy. Radiotherapy damages cancer cells. AZD1390 stops the cancer cells repairing themselves after radiotherapy so radiotherapy works better.
This is the first time people are having AZD1390.
The aims of the trial are to:
The following bullet points list the entry conditions for trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
Main entry conditions
You may be able to join this trial if all of the following apply.
You:
As well as the main entry conditions above, the following must also apply.
To join group A, you:
To join group C:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You:
Other
You:
This is a phase 1 trial. It is taking place in the United Kingdom and the United States. The researchers plan for about 132 people to take part.
You’ll join 1 of the following 3 groups. The group you join depends on the type of brain tumour you have.
Everyone will receive radiotherapy and AZD1390.
AZD1390
AZD1390 is a tablet. In all groups, the first few people taking part have a low dose of AZD1390. The next few people will have a higher dose if they don’t have any serious side effects. And so on, until they find the best dose. This is called a dose escalation study.
You:
During the 2 weeks after radiotherapy, the trial team will ask you to keep a diary to record each time you take AZD1390.
Radiotherapy
Before you have radiotherapy, you have a planning appointment as part of your care. This includes CT and MRI scans. The trial team will arrange this appointment for you.
You have standard radiotherapy every weekday.
This is for:
Samples for research
As well as routine blood tests, you have extra blood samples as part of this trial. Where possible, you give the samples at the same time as your routine blood tests. The researchers use the extra blood samples for a variety of tests.
For example, to:
You also give some extra urine samples.
The trial team will also ask to use tissue samples from previous biopsies or surgeries. But you don’t have to agree to this if you don’t want to. You can still take part in the trial.
You will see a doctor and have some tests done before you can take part. These include:
You take AZD1390 at the hospital before radiotherapy. You usually have it 3 hours before radiotherapy. Once you have finished radiotherapy, you will take AZD1390 at home for 2 weeks.
You will see the trial team for a check up:
In group A and group C, you will have an MRI scan and check up every 8 weeks. This continues for as long as the cancer stays the same.
As AZD1390 is a new drug, there may be some side effects we don’t know about yet. The trial team will monitor you during treatment and afterwards. You’ll have a phone number to call if you are worried about anything.
The possible side effects of AZD1390 are:
The trial team will ask you to avoid long periods in the sun, cover up, use adequate sunscreen protection and avoid tanning booths and sun beds during the trial and for 4 weeks after taking AZD1390.
We have more information about the side effects of radiotherapy to the brain.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Anthony Chalmers
AstraZeneca
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”